

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
----------------	------------------------------	------------------------------	---

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Betamethasone / Gentamicin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 1	H372: Causes damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : The image shows three red diamond-shaped hazard pictograms. The first shows a human head with a cracked eye. The second shows an exclamation mark inside a triangle. The third shows a dead tree and fish.

Signal word : Danger

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Hazard statements	:	H319 H360D H372 H410	Causes serious eye irritation. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention: P201 P273 P280	Obtain special instructions before use. Avoid release to the environment. Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Response: P308 + P313 P337 + P313 P391	IF exposed or concerned: Get medical advice/ attention. If eye irritation persists: Get medical advice/ attention. Collect spillage.

Hazardous components which must be listed on the label:

betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Propan-2-ol	67-63-0 200-661-7 603-117-00-0	Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336	>= 10 - < 20
Methyl p-Hydroxybenzoate	99-76-3 202-785-7	Aquatic Chronic 2; H411	>= 1 - < 2.5

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1	>= 0.025 - < 0.1
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Im- mune system, mus- cle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1,000 specific concentration limit STOT RE 1; H372 >= 0.01 % Repr. 1B; H360D >= 0.01 %	>= 0.025 - < 0.1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
----------------	------------------------------	------------------------------	---

If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks	: Causes serious eye irritation. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.
-------	---

4.3 Indication of any immediate medical attention and special treatment needed

Treatment	: Treat symptomatically and supportively.
-----------	---

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
------------------------------	--

Unsuitable extinguishing media	: None known.
--------------------------------	---------------

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides

5.3 Advice for firefighters

Special protective equipment	: In the event of fire, wear self-contained breathing apparatus.
------------------------------	--

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
----------------	------------------------------	------------------------------	---

for firefighters	Use personal protective equipment.
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
----------------------	--

6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
---------------------------	--

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	---

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
----------------	------------------------------	------------------------------	---

Advice on safe handling	: Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	: Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

7.3 Specific end use(s)

Specific use(s)	: No data available
-----------------	---------------------

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m ³	IE OEL
		OELV - 8 hrs (TWA) (total (vapour and particles))	150 ppm 470 mg/m ³	IE OEL
Propan-2-ol	67-63-0	OELV - 8 hrs	200 ppm	IE OEL

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

	(TWA)		
	Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body		
	OELV - 15 min (STEL)	400 ppm	IE OEL
	Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body		
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)
	Further information: OTO		
betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)
	Further information: Skin		
		Wipe limit	10 µg/100 cm ²
			Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local effects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local effects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day
Methyl p-Hydroxybenzoate	Workers	Inhalation	Long-term systemic effects	58.76 mg/m3
	Workers	Skin contact	Long-term systemic effects	9.8 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	14.49 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4.2 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4.16 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57.2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)
Propan-2-ol	Fresh water	140.9 mg/l
	Marine water	140.9 mg/l
	Intermittent use/release	140.9 mg/l
	Sewage treatment plant	2251 mg/l
	Fresh water sediment	552 mg/kg dry weight (d.w.)
	Marine sediment	552 mg/kg dry weight (d.w.)
	Soil	28 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	160 mg/kg food
Methyl p-Hydroxybenzoate	Fresh water	2.4 µg/l
	Freshwater - intermittent	0.112 mg/l
	Marine water	0.24 µg/l
	Sewage treatment plant	2 mg/l
	Fresh water sediment	0.0632 mg/kg dry weight (d.w.)
	Marine sediment	0.00632 mg/kg dry weight (d.w.)
	Soil	0.0115 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

	aerosols.
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to I.S. EN 14387
Filter type	: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	: liquid
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024
7.0 14.04.2025 5345524-00016 Date of first issue: 09.12.2019

pH	:	No data available
Viscosity	:	No data available
Viscosity, kinematic	:	No data available
Solubility(ies)	:	No data available
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	No data available
Particle characteristics	:	No data available
Particle size	:	Not applicable

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024
7.0 14.04.2025 5345524-00016 Date of first issue: 09.12.2019

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Components:

Propan-2-ol:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 25 mg/l Exposure time: 6 h Test atmosphere: vapour
Acute dermal toxicity	:	LD50 (Rabbit): > 5,000 mg/kg

Methyl p-Hydroxybenzoate:

Acute oral toxicity : LD50 (Rat, male): 2,100 mg/kg
Method: OECD Test Guideline 401

Gentamicin:

Acute oral toxicity	: LD50 (Rat): 8,000 - 10,000 mg/kg
	LD50 (Mouse): 10,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 0.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	: LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous
	LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular
	LDLo (Monkey): 30 mg/kg Application Route: Intravenous

betamethasone-

||Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

||| LD50 (Mouse): > 4,500 mg/kg
||| Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
||| Exposure time: 4 h

Skin corrosion/irritation

||| Not classified based on available information.

Components:

Propan-2-ol:

||| Species : Rabbit
||| Result : No skin irritation

Methyl p-Hydroxybenzoate:

||| Species : Rabbit
||| Result : No skin irritation

Gentamicin:

||| Species : Rabbit
||| Result : Mild skin irritation

betamethasone:

||| Species : Rabbit
||| Result : Mild skin irritation

Serious eye damage/eye irritation

||| Causes serious eye irritation.

Components:

Propan-2-ol:

||| Species : Rabbit
||| Result : Irritation to eyes, reversing within 21 days

Methyl p-Hydroxybenzoate:

||| Species : Rabbit
||| Result : No eye irritation

Gentamicin:

||| Species : Rabbit
||| Result : Mild eye irritation

betamethasone:

||| Species : Rabbit
||| Result : No eye irritation

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Propan-2-ol:

Test Type	:	Buehler Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Methyl p-Hydroxybenzoate:

Test Type	:	Maurer optimisation test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Gentamicin:

Remarks	:	No data available
---------	---	-------------------

betamethasone:

Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Propan-2-ol:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

Methyl p-Hydroxybenzoate:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
Genotoxicity in vitro		<p>: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative</p> <p>Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: positive</p>	
Genotoxicity in vivo		<p>: Test Type: Rodent dominant lethal test (germ cell) (in vivo) Species: Rat Application Route: Ingestion Method: OECD Test Guideline 478 Result: negative</p>	
Gentamicin:			
Genotoxicity in vitro		<p>: Test Type: In vitro mammalian cell gene mutation test Result: negative</p> <p>Test Type: Chromosome aberration test in vitro Result: equivocal</p>	
Genotoxicity in vivo		<p>: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intravenous injection Result: negative</p>	
betamethasone:			
Genotoxicity in vitro		<p>: Test Type: Bacterial reverse mutation assay (AMES) Result: negative</p> <p>Test Type: In vitro mammalian cell gene mutation test Result: negative</p> <p>Test Type: Chromosome aberration test in vitro Result: positive</p>	
Genotoxicity in vivo		<p>: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal</p>	
Germ cell mutagenicity- Assessment		<p>: Weight of evidence does not support classification as a germ cell mutagen.</p>	

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Components:

Propan-2-ol:

Species	:	Rat
Application Route	:	inhalation (vapour)
Exposure time	:	104 weeks
Method	:	OECD Test Guideline 451
Result	:	negative

Gentamicin:

Carcinogenicity - Assessment	:	No data available
------------------------------	---	-------------------

Reproductive toxicity

May damage the unborn child.

Components:

Propan-2-ol:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

Methyl p-Hydroxybenzoate:

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rabbit Application Route: Ingestion Result: negative
-------------------------------	---	---

Gentamicin:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Fertility: NOAEL: 20 mg/kg body weight Result: No significant adverse effects were reported
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: 3.6 mg/kg body weight Result: No embryo-foetal toxicity
	:	Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-foetal toxicity

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

		Test Type: Embryo-foetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.
		Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.
Reproductive toxicity - Assessment	:	Positive evidence of adverse effects on development from human epidemiological studies.
betamethasone:		
Effects on foetal development	:	Species: Rabbit Application Route: Intramuscular Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.
		Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.42 mg/kg body weight Result: Malformations were observed.
		Species: Mouse Application Route: Intramuscular Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Malformations were observed.
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Gentamicin:

Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

betamethasone:

Target Organs	: Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Propan-2-ol:

Species	: Rat
NOAEL	: 12.5 mg/l
Application Route	: inhalation (vapour)
Exposure time	: 104 Weeks

Methyl p-Hydroxybenzoate:

Species	: Rat
NOAEL	: 250 mg/kg
LOAEL	: 1,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days
Method	: OECD Test Guideline 407

Gentamicin:

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Intramuscular
Exposure time	: 12 Months
Target Organs	: Kidney
Symptoms	: Vomiting, Salivation

Species	: Monkey
LOAEL	: 50 mg/kg
Application Route	: Subcutaneous
Exposure time	: 3 Weeks
Target Organs	: Kidney, inner ear

Species	: Monkey
LOAEL	: 6 mg/kg
Application Route	: Intramuscular
Exposure time	: 3 Weeks
Target Organs	: Blood, Kidney, inner ear, Liver

Species	: Rat
NOAEL	: 5 mg/kg
LOAEL	: 10 mg/kg
Application Route	: Intramuscular
Exposure time	: 52 Weeks

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

||| Target Organs : Kidney, Blood

||| Species : Rat
NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

betamethasone:

||| Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d
Target Organs : Pituitary gland, Immune system, muscle

||| Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

||| Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

||| Species : Dog
LOAEL : 0.05 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Blood, thymus gland, Adrenal gland

Aspiration toxicity

||| Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

||| Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Experience with human exposure

Components:

Gentamicin:

Ingestion : Target Organs: Kidney
Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

betamethasone:

Inhalation : Target Organs: Adrenal gland
Skin contact : Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1,050 mg/l
Exposure time: 16 h

Methyl p-Hydroxybenzoate:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 59.5 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 11.2 mg/l
Exposure time: 48 h
Method: ISO 6341

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 91 mg/l
Exposure time: 72 h
Method: ISO 8692

EC10 (Pseudokirchneriella subcapitata (green algae)): 31 mg/l
Exposure time: 72 h
Method: ISO 8692

Toxicity to fish (Chronic toxicity) : NOEC: 0.024 mg/l
Exposure time: 70 d
Species: Danio rerio (zebra fish)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.2 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Gentamicin:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 100

Toxicity to microorganisms : EC50 : 288.7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity) : 1

betamethasone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

		mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC: 0.052 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
		NOEC: 0.07 µg/l Exposure time: 219 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 229
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 8 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1,000

12.2 Persistence and degradability

Components:

Propan-2-ol:

Biodegradability	:	Result: rapidly degradable
BOD/COD	:	BOD: 1,19 (BOD5) COD: 2,23 BOD/COD: 53 %

Methyl p-Hydroxybenzoate:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 89 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

Gentamicin:

Biodegradability	:	Result: rapidly degradable Biodegradation: 100 % Exposure time: 28 d Method: OECD Test Guideline 314
------------------	---	---

12.3 Bioaccumulative potential

Components:

Propan-2-ol:

Partition coefficient: n-	:	log Pow: 0.05
---------------------------	---	---------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

|||octanol/water

Methyl p-Hydroxybenzoate:

|||Partition coefficient: n-octanol/water : log Pow: 1.98

Gentamicin:

|||Partition coefficient: n-octanol/water : log Pow: < -2

betamethasone:

|||Partition coefficient: n-octanol/water : log Pow: 2.11

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5345524-00016 Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
IATA	:	UN 3082

14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (betamethasone)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN		
Packing group	:	III
Classification Code	:	M6
Hazard Identification Number	:	90
Labels	:	9
 ADR		
Packing group	:	III

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
7.0	14.04.2025	5345524-00016	Date of first issue: 09.12.2019

Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks	: Not applicable for product as supplied.
----------------	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

: Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer

: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

: Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

: Not applicable

REACH - List of substances subject to authorisation (Annex XIV)

: Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Quantity 1
100 t
Quantity 2
200 t

E1
ENVIRONMENTAL
HAZARDS

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5345524-00016	Date of last issue: 04.12.2024 Date of first issue: 09.12.2019
----------------	------------------------------	------------------------------	---

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H225 : Highly flammable liquid and vapour.
H319 : Causes serious eye irritation.
H330 : Fatal if inhaled.
H336 : May cause drowsiness or dizziness.
H360D : May damage the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure
IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL) : Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good La-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5345524-00016

Date of last issue: 04.12.2024
Date of first issue: 09.12.2019

boratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Irrit. 2	H319
Repr. 1B	H360D
STOT RE 1	H372
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN